Abstract
Kathryn J. Ruddy, Damé Idossa, Dalliah M. Black, Kimberly S. Corbin
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Breast cancer statistics 2024
2024
Global patterns and trends in breast cancer incidence and mortality across 185 countries
10.1038/s41591-025-03502-3 · 2025
Impact of Covid-19 on breast cancer screening
10.31557/apjcp.2024.25.8.2703 · 2024
Understanding susceptibility to breast cancer: from risk factors to prevention strategies
10.3390/ijms26072993 · 2025
Updates in the evaluation and management of breast cancer
10.1016/j.mayocp.2018.03.025 · 2018
Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline
10.1200/jco.23.02225 · 2024
WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast
10.1111/his.14091 · 2020
Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial
10.1200/jco.2015.60.8133 · 2015
Molecular markers in the diagnosis and staging of breast cancer
10.1053/srao.2002.35249 · 2002
Standard-of-care treatment for HER2+ metastatic breast cancer and emerging therapeutic options
10.1177/11782234241234418 · 2024
Advances in systemic therapies for triple negative breast cancer
10.1136/bmj-2022-071674 · 2023
New treatment approaches for triple-negative breast cancer
10.1200/edbk-25-481154 · 2025
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
10.1016/j.annonc.2023.05.008 · 2023
Implications for breast cancer restaging based on the 8th edition AJCC Staging Manual
10.1097/sla.0000000000003071 · 2020
Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group
10.1093/jnci/djaa201 · 2021
Molecular portraits of human breast tumours
10.1038/35021093 · 2000
Clinical implications of the intrinsic molecular subtypes of breast cancer
10.1016/j.breast.2015.07.008 · 2015
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
10.1056/nejm199511303332203 · 1995
Contralateral prophylactic mastectomy: challenging considerations for the surgeon
10.1245/s10434-015-4758-y · 2015
Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks
10.1245/s10434-016-5443-5 · 2016
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
10.1016/s1470-2045(10)70207-2 · 2010
Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial
10.1001/jamaoncol.2023.3759 · 2023
Axillary surgery in breast cancer — primary results of the INSEMA trial
10.1056/nejmoa2412063 · 2025
Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)
10.1186/s12885-017-3443-x · 2017
No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial
10.1186/s12885-022-09273-1 · 2022
A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy
10.1097/sla.0000000000002313 · 2018
Selective elimination of breast surgery for invasive breast cancer: a nonrandomized clinical trial
10.1001/jamaoncol.2025.0207 · 2025
Breast cancer cryoablation fundamentals past and present: technique optimization and imaging pearls
10.1016/j.acra.2023.05.019 · 2023
Cryoablation without excision for early-stage breast cancer: ICE3 trial 5-year follow-up on ipsilateral breast tumor recurrence
10.1245/s10434-024-16181-0 · 2024
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials
10.1016/s0140-6736(11)61629-2 · 2011
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
10.1016/s0140-6736(14)60488-8 · 2014
Breast-conserving surgery with or without irradiation in early breast cancer
10.1056/nejmoa2207586 · 2023
Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial
10.1200/jco.20.00650 · 2020
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
10.1016/s1470-2045(24)00661-2 · 2025
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
10.1016/s0140-6736(20)30932-6 · 2020
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
10.1016/s0140-6736(23)00619-0 · 2023
Omitting regional nodal irradiation after response to neoadjuvant chemotherapy
10.1056/nejmoa2414859 · 2025
Ten-year survival after postmastectomy chest-wall irradiation in breast cancer
10.1056/nejmoa2412225 · 2025
A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505)
10.1016/j.ijrobp.2024.07.002 · 2024
Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical trial
10.1001/jamaoncol.2024.2652 · 2024
Use of ctDNA in early breast cancer: analytical validity and clinical potential
10.1038/s41523-024-00653-3 · doi-reference
Clinical validity and clinical utility of Ki67 in early breast cancer
10.1177/17588359221122725 · doi-reference
International Immuno-Oncology Biomarker Working Group. Tumor-infiltrating lymphocytes in triple-negative breast cancer
10.1001/jama.2024.3056 · doi-reference
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
10.1016/j.annonc.2026.03.008 · doi-reference
Overall survival with palbociclib and fulvestrant in advanced breast cancer
10.1056/nejmoa1810527 · doi-reference
Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2501796 · doi-reference
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
10.1016/j.annonc.2020.11.011 · doi-reference
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
10.1016/s1470-2045(18)30292-4 · doi-reference
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
10.1016/j.annonc.2021.05.353 · doi-reference
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
10.1093/annonc/mdy155 · doi-reference
The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial
10.1001/jamaoncol.2019.4782 · doi-reference
MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy
10.1200/jco.2017.73.7585 · doi-reference
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3
10.1016/j.annonc.2024.04.013 · doi-reference
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
10.1200/jco.2017.75.6155 · doi-reference
Palbociclib and letrozole in advanced breast cancer
10.1056/nejmoa1607303 · doi-reference
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis
10.1093/neuonc/noaa285 · doi-reference
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
10.1016/s0140-6736(22)02420-5 · doi-reference
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
10.1016/j.ejca.2023.01.031 · doi-reference
OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
10.1093/annonc/mdz012 · doi-reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · doi-reference
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
10.1016/s0140-6736(20)32531-9 · doi-reference
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
10.1056/nejmoa2202809 · doi-reference
Survival following CDK4/6 inhibitor therapy for hormone receptor-positive, ERBB2-negative metastatic breast cancer
10.1001/jamanetworkopen.2024.61067 · doi-reference
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
10.1056/nejmoa2203690 · doi-reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01
10.1200/jco.24.00920 · doi-reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · doi-reference
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
10.1007/s00109-021-02136-5 · doi-reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · doi-reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · doi-reference
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
10.1093/annonc/mdu456 · doi-reference
Imlunestrant with or without abemaciclib in advanced breast cancer
10.1056/nejmoa2410858 · doi-reference
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial
10.1200/jco.22.00338 · doi-reference
Capivasertib in hormone receptor-positive advanced breast cancer
10.1056/nejmoa2214131 · doi-reference
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
10.1056/nejmoa1813904 · doi-reference
Phosphoinositide 3-kinase (PI3K) inhibitors and breast cancer: an overview of current achievements
10.3390/cancers15051416 · doi-reference
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges
10.1038/s41416-021-01564-x · doi-reference
Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial
10.1200/jco.22.02392 · doi-reference
Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2404625 · doi-reference
Overall survival with ribociclib plus letrozole in advanced breast cancer
10.1056/nejmoa2114663 · doi-reference
Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review
10.1001/jamaoncol.2023.2000 · doi-reference